Deep Partner Integration,
KBI’s has leveraged our deep manufacturing expertise to design our Geneva, Switzerland facility. In partnership with Selexis SA, we are able to provide “GENE to GMP in 9 Months” – the most robust and fastest service offering in the biopharmaceutical industry. By predictably getting cGMP material for your clinical study, we help you concentrate on the other critical components of your development program.
Pharmaceutical Contract Manufacturing
That Helps You Reach the Clinic Faster
Our 5,600-square-meter biologic bulk drug substance manufacturing facility is scheduled to be operational by mid-2022 and will create more than 200 technical positions in development, operations, and quality assurance.
- Dual 2,000 L Xcellerex™ single-use bioreactor upstream suite with associated downstream processing
- Clinical manufacturing facility is co-located with Selexis to offer rapid Gene to GMP™ 9 month timelines
- Combined 8,700 sq meters for KBI/Selexis, 5,600 sq meters dedicated to KBI service offerings
- First full-scale, cGMP batches projected to be produced in Q3 2022
Countdown to Grand Opening
Find Out How KBI Can Meet
Your Drug Substance Supply Needs
President and CEO of KBI Biopharma and CEO of Selexis SA
This purpose build facility is a demonstration of our continued commitment to provide a local presence for European customers. Collocating KBI with Selexis offers an easy, simple transition from Selexis’ innovative cell line technologies and KBI’s world-renowned expertise in biologics manufacturing.
Chief Operating Officer of KBI Biopharma
As science progresses, research and treatments become increasingly complex and sophisticated, we are fully prepared to keep pace with our clients’ needs by providing the latest life science discovery and development technology.